Okuyama Toshiro, Higashi Takahiro, Edagawa Ai, Nagata Shigeyuki, Hashimoto Kenkichi, Saeki Hiroshi, Oki Eiji, Uchiyama Hideaki, Kawanaka Hirofumi, Morita Masaru, Tateishi Masahiro, Korenaga Daisuke, Yaita Hidemichi, Takenaka Kenji
Department of surgery, Fukuoka City Hospital 13-1 Yoshizuka-honmachi Hakata-ku, Fukuoka city, 812-0046 Japan.
Fukuoka Igaku Zasshi. 2012 Jul;103(7):138-44.
The prognosis of gastric cancer patients undergoing curability B surgery was retrospectively examined to determine the effectiveness of the administration of oral anti-cancer drugs as postoperative adjuvant chemotherapy.
This study was based on the outcomes of 86 potentially curative patients who had undergone curability B resection of gastric cancer with or without the subsequent administration of oral 5-fluorouracil analogue. There were 21 patients who underwent surgery alone with no oral anti-cancer agents (group A) and 65 patients who were treated postoperatively, mainly with UFT (Tegafur and uracil; group B). This study compared the ten-year survival times of these two groups using univariate and multivariate analyses.
The amount of UFT in group B was 354.2 +/- 122.0 mg and the administration period was 11.7 +/- 7.2 months. The backgrounds showed significantly more older patients in group A compared than group B (P = 0.0002). A univariate analysis showed the ten-year survival rate in group B to be higher than group A (P = 0.0079). A multivariate analysis showed that the postoperative administration of UFT was an independent factor associated with prolongation of survival times as well as the extent of lymph nodes metastasis and pathological stage (P = 0.0096).
This study provided conventional evidence that postoperative administration of oral 5-fluorouracil analogue is associated with better long-term prognoses in patients undergoing curability B resection for gastric carcinoma.
回顾性研究接受B根治性手术的胃癌患者的预后情况，以确定口服抗癌药物作为术后辅助化疗的有效性。
本研究基于86例可能治愈的患者的结局，这些患者接受了胃癌的B根治性切除术，术后接受或未接受口服5-氟尿嘧啶类似物治疗。其中21例患者仅接受手术，未使用口服抗癌药物（A组），65例患者术后主要接受优福定（替加氟和尿嘧啶）治疗（B组）。本研究采用单因素和多因素分析比较了这两组患者的十年生存时间。
B组优福定的用量为354.2±122.0mg，给药期为11.7±7.2个月。背景资料显示，A组老年患者明显多于B组（P = 0.0002）。单因素分析显示，B组的十年生存率高于A组（P = 0.0079）。多因素分析显示，术后给予优福定是与生存时间延长以及淋巴结转移范围和病理分期相关的独立因素（P = 0.0096）。
本研究提供了常规证据，表明对于接受胃癌B根治性切除术的患者，术后给予口服5-氟尿嘧啶类似物与更好的长期预后相关。
